Emily S Brouwer1, Sonia Napravnik, Joseph J Eron, Brant Stalzer, Michelle Floris-Moore, Ross J Simpson, Til Stürmer. 1. From the aDepartment of Pharmacy Practice and Science, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY; bDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; cDepartment of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC; and dDepartment of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
BACKGROUND: Cohort studies have demonstrated greater risk of myocardial infarction (MI) associated with specific antiretroviral use, while meta-analyses of randomized controlled trials (RCTs) have not. These differences may be due to inherent biases in the observational study design or to the limited duration of randomized trials. We conducted a new-user, active-comparator cohort study emulating an RCT comparing the initiation of several antiretrovirals as part of combination antiretroviral therapy (cART) and MI. METHODS: We included North Carolina (NC) Medicaid beneficiaries infected with human immunodeficiency virus between 2002 and 2008 who were previously untreated with cART. We compared hazard ratios (HRs) and 95% confidence intervals (CIs) of MI between abacavir and tenofovir recipients, and lopinavir-ritonavir or atazanavir recipients and nonnucleoside reverse transcriptase inhibitor (NNRTI) recipients. We adjusted for confounding through inverse probability weighting methods. RESULTS: There were 3481 NC Medicaid new cART recipients who contributed 6399 person-years and experienced 38 MI events. Receiving abacavir compared with tenofovir as part of cART was associated with an increased rate of MI (unadjusted HR = 2.70 [95% CI = 1.24-5.91]; adjusted HR = 2.05 [0.72-5.86]). Point estimates also suggest a relationship between receipt of atazanavir or lopinavir-ritonavir compared with an NNRTI and MI, although estimates were imprecise. CONCLUSIONS: We found an increased rate of MI among patients initiating abacavir compared with tenofovir, although the association was decreased after confounding adjustment. Without a very large prospective comparative clinical trial, a much larger observational study of patients initiating cART would be needed to better define this apparent association.
BACKGROUND: Cohort studies have demonstrated greater risk of myocardial infarction (MI) associated with specific antiretroviral use, while meta-analyses of randomized controlled trials (RCTs) have not. These differences may be due to inherent biases in the observational study design or to the limited duration of randomized trials. We conducted a new-user, active-comparator cohort study emulating an RCT comparing the initiation of several antiretrovirals as part of combination antiretroviral therapy (cART) and MI. METHODS: We included North Carolina (NC) Medicaid beneficiaries infected with human immunodeficiency virus between 2002 and 2008 who were previously untreated with cART. We compared hazard ratios (HRs) and 95% confidence intervals (CIs) of MI between abacavir and tenofovir recipients, and lopinavir-ritonavir or atazanavir recipients and nonnucleoside reverse transcriptase inhibitor (NNRTI) recipients. We adjusted for confounding through inverse probability weighting methods. RESULTS: There were 3481 NC Medicaid new cART recipients who contributed 6399 person-years and experienced 38 MI events. Receiving abacavir compared with tenofovir as part of cART was associated with an increased rate of MI (unadjusted HR = 2.70 [95% CI = 1.24-5.91]; adjusted HR = 2.05 [0.72-5.86]). Point estimates also suggest a relationship between receipt of atazanavir or lopinavir-ritonavir compared with an NNRTI and MI, although estimates were imprecise. CONCLUSIONS: We found an increased rate of MI among patients initiating abacavir compared with tenofovir, although the association was decreased after confounding adjustment. Without a very large prospective comparative clinical trial, a much larger observational study of patients initiating cART would be needed to better define this apparent association.
Authors: Andy I Choi; Eric Vittinghoff; Steven G Deeks; Cristin C Weekley; Yongmei Li; Michael G Shlipak Journal: AIDS Date: 2011-06-19 Impact factor: 4.177
Authors: Melanie A Thompson; Judith A Aberg; Jennifer F Hoy; Amalio Telenti; Constance Benson; Pedro Cahn; Joseph J Eron; Huldrych F Günthard; Scott M Hammer; Peter Reiss; Douglas D Richman; Giuliano Rizzardini; David L Thomas; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2012-07-25 Impact factor: 56.272
Authors: Claudette S Satchell; Jane A O'Halloran; Aoife G Cotter; Aaron J Peace; Eileen F O'Connor; Anthony F Tedesco; Eoin R Feeney; John S Lambert; Gerard J Sheehan; Dermot Kenny; Patrick W G Mallon Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: Prema Menezes; William C Miller; David A Wohl; Adaora A Adimora; Peter A Leone; William C Miller; Joseph J Eron Journal: PLoS One Date: 2011-07-13 Impact factor: 3.240
Authors: Shreya G Rao; Karla I Galaviz; Hawkins C Gay; Jingkai Wei; Wendy S Armstrong; Carlos Del Rio; K M Venkat Narayan; Mohammed K Ali Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Chanelle M Diaz; Eddy R Segura; Paula M Luz; Jesse L Clark; Sayonara R Ribeiro; Raquel De Boni; Leonardo Eksterman; Rodrigo Moreira; Judith S Currier; Valdiléa G Veloso; Beatriz Grinsztejn; Jordan E Lake Journal: BMC Infect Dis Date: 2016-08-08 Impact factor: 3.090
Authors: Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren Journal: BMC Med Date: 2016-03-31 Impact factor: 8.775